Novo Nordisk’s Oral Semaglutide Study Confirms Efficacy for Weight Management

The beginning of 2026 marks a significant advancement in weight management therapies. Following its recent approval by the U.S. Food and Drug Administration (FDA), the 25 mg oral semaglutide tablet, marketed as Wegovy, is now available in the United States. This medication is intended for chronic weight management as well as for lowering the risk of major adverse cardiovascular events among adults who are overweight or obese and have existing cardiovascular conditions.

Results from the OASIS 4 clinical trial, recently published in the New England Journal of Medicine, indicate that the daily 25 mg dose of oral semaglutide effectively resulted in considerable weight loss and enhancements in physical functionality. This mid-dose oral option provides a convenient alternative for patients who may prefer taking a pill instead of receiving standard weekly injections or opting for higher-dose oral medications.

The study's authors noted that many patients favor oral administration primarily due to needle aversion and skin reactions associated with injections. They also emphasized that oral medications do not necessitate refrigeration, which may expand access to obesity treatments in regions where refrigeration availability is limited.

This randomized, double-blind trial spanned 71 weeks and included 307 non-diabetic participants across four countries. The eligible participants had either a body mass index (BMI) of 30 or higher or a BMI of 27 and at least one obesity-related complication, such as hypertension or obstructive sleep apnea.

The findings revealed that participants taking the 25 mg oral semaglutide experienced an estimated average weight loss of 13.6% from baseline, compared to a mere 2.2% in the placebo group. This data positions the medication as a strategic middle-ground option for those who do not require the maximum dosing of 50 mg but desire improved results compared to lower oral dosages.

The study concludes that the oral pills' convenience may increase accessibility and compliance among patients in diverse geographic areas. In addition to primary weight loss assessment, the trial also monitored various secondary endpoints, including reductions in waist circumference and improvements in systolic blood pressure.

Participants in the semaglutide group showed a significantly higher likelihood of achieving weight loss milestones, such as reductions of 10%, 15%, and even 20% or more, compared to those on placebo. Furthermore, there was a notable enhancement in physical function scores measured through the IWQOL-Lite-CT assessment, which correlate with improved mobility and overall daily life quality.

"The weight loss and enhancements in metabolic markers observed with oral semaglutide are substantial and will have a positive impact on obesity medicine and related metabolic conditions," stated Sean Wharton, the primary author and head of the Wharton Weight Management Clinic in Burlington, Canada.

As a GLP-1 receptor agonist, oral semaglutide acts by mimicking a natural hormone that controls appetite and caloric intake. However, the 25 mg dose was linked to a higher incidence of side effects compared to the placebo, with gastrointestinal issues—primarily nausea and diarrhea—reported by 74% of those in the semaglutide group against 42.2% in the placebo group. These outcomes align with the established safety profile of the GLP-1 medication class.

Overall, the study underscores the potential of oral semaglutide as a significant option in the landscape of obesity management.